C Ray Therapeutics, a Chengdu-based radiopharmaceutical contract research, development, and manufacturing organization, used the week to spotlight its integrated Chengdu hub and expanding role in the radioligand therapy value chain. The company positioned its Chengdu Medical City site as a one-stop CRDMO platform, covering process development, radiolabeling, cGMP manufacturing, and cold-chain logistics for global partners.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
At the XDC 2026 conference in Chengdu, C Ray convened isotope producers, ligand innovators, and clinical-stage developers, underscoring the city’s emergence as a radiopharmaceutical hub supported by infrastructure and policy. The firm highlighted industry trends such as diversification of ligand platforms, improved isotope supply, and growth in new therapeutic modalities.
A key development was C Ray’s strategic partnership with SHINE Technologies, securing long-term, GMP-grade, no-carrier-added lutetium-177 from SHINE’s Cassiopeia facility for exclusive distribution in mainland China, subject to existing SHINE relationships. The company plans to supply this Lu-177 to Chinese radiopharma developers, biotech firms, and hospitals, leveraging its 28,000-square-meter Chengdu site for conjugation, fill-and-finish, and quality control.
By combining Lu-177 access with existing actinium-225 capabilities, C Ray is aiming to become a core infrastructure player for targeted radiopharmaceutical therapies from preclinical through Phase III. Management emphasized that secure, reliable isotope sourcing is becoming a regulatory and commercial differentiator as Asian radiopharma pipelines mature.
The company also showcased automation partnerships with TRUKING and STÄUBLI to deploy Stericlean robotic systems for GMP-compliant aseptic manufacturing. It continued to promote localized alpha therapies using Ra-224 for peritoneal metastases and discussed Pb-212 supply challenges and thorium-based production approaches from partners such as Thor Medical.
C Ray’s co-organizing role at the International RDC Sub-Forum at XDC 2026 reinforced its thought-leadership ambitions and ecosystem-building strategy. Engagement with NorthStar Medical Radioisotopes, Navigo Proteins, Oncoinvent, and others suggests a focus on integrating isotope supply, advanced manufacturing, and next-generation ligand design.
From a financial and strategic perspective, these developments collectively strengthen C Ray’s positioning as a key platform partner in China’s radiopharmaceutical sector. While no specific contracts or financial metrics were disclosed, the expanded isotope access, automation investments, and deepening global collaborations could enhance the company’s competitive standing and support long-term growth in targeted oncology and nuclear medicine markets.
Overall, the week marked a period of consolidation and visibility building for C Ray Therapeutics, as it leveraged Chengdu’s hub status and new supply agreements to reinforce its role in the global radiopharmaceutical supply chain.